Aug 8 |
Nektar Therapeutics Reports Second Quarter 2024 Financial Results
|
Aug 1 |
Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets
|
Jul 16 |
Nektar Therapeutics' (NASDAQ:NKTR) large institutional owners must be happy as stock continues to impress, up 13% over the past week
|
Jun 21 |
Nektar Therapeutics Likely To Drift And Wobble Ahead Of Key Phase II Data In 2025
|
Jun 12 |
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
|
Jun 5 |
Nektar Therapeutics' (NASDAQ:NKTR) investors will be pleased with their stellar 130% return over the last year
|
May 30 |
Nektar Management to Present at Upcoming Investor Conferences
|
May 30 |
Russell 3000: Inovio, Ocugen among healthcare additions; Assertio, Ginkgo Bioworks among deletions
|
May 28 |
Nektar files to sell 25M shares of common stock for holders
|
May 10 |
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
|